Regulus Announces Merger Agreement with Novartis

Regulus ( (RGLS) ) has issued an update.

On April 29, 2025, Regulus Therapeutics entered into a merger agreement with Novartis AG, under which Novartis will acquire Regulus for $7.00 per share in cash, with an additional $7.00 per share contingent on regulatory approval of Regulus’ lead product candidate, farabursen. This transaction, valued at up to $1.7 billion, is expected to close in the second half of 2025, subject to customary conditions. The merger aims to leverage Novartis’ global capabilities to advance farabursen, a potential first-in-class treatment for autosomal dominant polycystic kidney disease (ADPKD), a condition with limited treatment options. The boards of both companies have unanimously approved the merger, which is anticipated to enhance Regulus’ industry positioning and provide significant benefits to stakeholders.

Spark’s Take on RGLS Stock

According to Spark, TipRanks’ AI Analyst, RGLS is a Neutral.

Regulus Therapeutics presents a mixed outlook. The company’s strong technical momentum and positive clinical trial results are offset by severe financial performance challenges, with no current sales and ongoing cash flow issues. The stock’s speculative nature is underscored by a negative P/E ratio, appealing primarily to investors focused on long-term biotech prospects rather than immediate financial stability.

To see Spark’s full report on RGLS stock, click here.

More about Regulus

Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. The company has leveraged its expertise in oligonucleotide drug discovery to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus is headquartered in San Diego, CA.

YTD Price Performance: 123.72%

Average Trading Volume: 1,274,463

Technical Sentiment Signal: Hold

Current Market Cap: $231.2M

For a thorough assessment of RGLS stock, go to TipRanks’ Stock Analysis page.